Last updated: February 23, 2026
What is the Drug?
The National Drug Code (NDC) 68462-0324 corresponds to Diphenhydramine Hydrochloride, an antihistamine used primarily for allergy relief, sleep aid, and cold symptoms. It is marketed under various brand names, including Benadryl, and available in generic forms. It is classified as an OTC (over-the-counter) medication but also available via prescription for specific indications.
Market Size and Demand
Current Market Share
- The global antihistamine market was valued at approximately $4 billion in 2022.
- Diphenhydramine accounts for an estimated 35% of OTC antihistamine sales in the U.S. (IQVIA, 2022).
- The drug’s prevalence covers both OTC and prescription segments, with OTC use comprising 75% of total sales.
Sales Volume
- Estimated U.S. annual sales volume of diphenhydramine formulations (including NDC 68462-0324): over 100 million units.
- The majority of sales originate from OTC tablets and capsules, with seasonal peaks during allergy seasons and end-of-year cold remedies.
Competitive Landscape
| Company |
Market Share |
Key Brands |
Price Range (per unit) |
| Johnson & Johnson |
50% |
Benadryl |
$0.10-$0.20 |
| Sandoz |
25% |
Generic diphenhydramine |
$0.05-$0.15 |
| Other Generics |
25% |
Various |
$0.03-$0.12 |
Regulatory Environment
- OTC status under the FDA; no premium pricing due to OTC designation.
- Prescription options have niche markets for severe allergy or sleep disorders.
Price Trends and Projection
Historical Price Trends (last 3 years)
- OTC unit prices have remained stable, averaging $0.10 per capsule.
- Generic forms consistently undercut brand-name prices by 25-40%.
Factors Affecting Future Pricing
- Manufacturing Costs: Slight increases due to raw material price volatility.
- Regulatory Changes: No expected significant changes; OTC status remains stable.
- Market Competition: Entry of new generic manufacturers could drive prices downward.
- Supply Chain Dynamics: Potential disruptions could temporarily increase prices.
Price Projection (Next 3-5 Years)
| Year |
Predicted Price Range (per unit) |
Assumptions |
| 2023 |
$0.09 - $0.12 |
Stable demand, moderate raw material costs |
| 2024 |
$0.08 - $0.11 |
Increased generic competition, raw material pressures |
| 2025 |
$0.07 - $0.10 |
Further market saturation, potential supply chain adjustments |
"Average retail prices" are expected to decline marginally, driven by increased generics and competitive pressures.
Investment and Business Implications
- Manufacturers: Lower prices could pressure margins; efficiency improvements remain critical.
- Distributors: Stable demand supports consistent cash flow.
- Market Entrants: Opportunities exist in generic manufacturing due to low barriers and stable demand.
Summary of Key Data
- Market size: $4 billion globally (2022).
- U.S. OTC sales: over 75 million units annually.
- Competitive landscape: Dominated by Johnson & Johnson and various generic players.
- Price stability: $0.10-$0.20 range for brand-name, $0.03-$0.15 for generics.
- Price outlook: Gradual decline to $0.07-$0.10 over five years.
Key Takeaways
- The diphenhydramine market remains sizable, with stable demand driven by OTC sales.
- Price competition among generics is likely to reduce unit prices gradually.
- Industry pressures include raw material costs, supply chain stability, and regulatory environment.
- Opportunities exist for generic firms due to low market entry barriers and steady demand.
- Market movements are predictable within a narrow price corridor, barring supply shocks.
FAQs
1. Is NDC 68462-0324 a brand-name or generic drug?
The NDC corresponds to a generic formulation of diphenhydramine hydrochloride.
2. How might regulatory changes impact pricing?
Regulatory stability suggests limited impact; changes favoring OTC status could standardize prices.
3. What are primary market risks?
Supply chain disruptions, raw material cost increases, and intensified pricing pressures from new entrants.
4. Is there seasonal variation in sales?
Yes. Cold and allergy seasons result in peak demand, especially in fall and spring.
5. Are there patent considerations for this NDC?
No, diphenhydramine has been off-patent for decades, facilitating generic competition.
References
[1] IQVIA. (2022). OTC antihistamine market report.
[2] FDA. (2020). Over-the-counter drug monograph process.
[3] MarketWatch. (2022). Global antihistamine market size and forecasts.
